Adaptations to the model include the addition of breast cancer therapies and their potential influence on biomarkers[51,52] as well as the addition of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3). This evidence concerns the gene IGF1 and breast carcinoma.